LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42225101无 PMCID | 2026-Jun | 0.95 | The record is a phase III randomized, double-blind, placebo-controlled trial in human oncology (prostate cancer) with a drug-containing intervention (aglatimagene besadenovec plus valacyclovir) and a primary time-to-event efficacy endpoint (disease-free survival). It meets all eligibility criteria for the oncology KM digitization cohort. | 无 KM 图 |
| Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China.Asia Pac J Clin NutrPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42242853PMC13236445 | 2026-Jun | 0.95 | The study is a randomized Phase III trial in oncology patients with a primary efficacy endpoint, but the endpoint is a change in a nutritional biomarker (pre-albumin), not a time-to-event outcome like OS or PFS. The intervention is a nutritional formula, not a drug, and there is no Kaplan-Meier analysis or hazard ratio. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. | 无 KM 图 |
| Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking Individuals With Alcohol Use Disorder.Alcohol Clin Exp Res (Hoboken)已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。 | PMID 42246466PMC13238437 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.Eur J Neurol | PMID 42257510PMC13244661 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 部分完成 |
| Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.Alzheimers Dement疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 42273802PMC13254682 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).JCO Glob Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42308452无 PMCID | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217).Dig Endosc疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 km;FIGURE 3:AI 判定为 multi panel km。 | PMID 42313516PMC13277963 | 2026-Jun | 0.85 | While this is a Phase III randomized oncology trial with drug interventions and a time-to-event endpoint (stricture-free survival), the primary endpoint is prevention of a post-procedural complication (esophageal stricture), not a direct oncology efficacy endpoint for the malignant neoplasm itself. Therefore, it does not meet the specific requirement for a primary/key secondary oncology efficacy endpoint (OS, PFS, DFS, etc.). | 无 KM 图 |
| Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:非 KM 图。 | PMID 42339511PMC13291802 | 2026-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.Health Technol AssessPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42370465无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial.Health Technol Assess疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42381494PMC13334417 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41865758无 PMCID | 2026-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42208560无 PMCID | 2026-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42208561无 PMCID | 2026-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42202319无 PMCID | 2026-May-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.Clin Exp DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41206702无 PMCID | 2026-May-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.BMJ Open已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 multi panel km;另有 1 张未列出。 | PMID 42192627PMC13202101 | 2026-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42150581无 PMCID | 2026-May-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42000149无 PMCID | 2026-May-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.Signal Transduct Target Ther | PMID 42168151PMC13194736 | 2026-May-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.Acta Derm Venereol | PMID 42163822PMC13191219 | 2026-May-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.Lupus Sci Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 42167880PMC13202072 | 2026-May-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.Clin Infect Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。 | PMID 41560517PMC13189652 | 2026-May-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.J Clin Oncol | PMID 41564372PMC13185729 | 2026-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图;Figure 4::非 KM 图。 | PMID 41616224PMC12866954 | 2026-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.J Clin OncolAI 判定该论文不进入自动 KM 提取:The record is explicitly described as a Phase II trial. | PMID 42018958无 PMCID | 2026-May-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.BMC Oral Health入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42163196PMC13217672 | 2026-May-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41697953无 PMCID | 2026-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42018318PMC13103881 | 2026-May-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.J Am Heart Assoc已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 42132192PMC13279551 | 2026-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42154070无 PMCID | 2026-May-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.Aesthet Surg J已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 1 张未列出。 | PMID 41692601PMC13182903 | 2026-May-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42114550无 PMCID | 2026-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42134354无 PMCID | 2026-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42134356无 PMCID | 2026-May-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Feasibility, acceptability and efficacy of a nurse-led palliative care health coaching intervention (Educate, Nurture, Advise before Life Ends) for patients with heart failure and their caregivers in Singapore: a randomised wait-list controlled pilot study of health coaching in Asian heart failure.BMJ Open入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42152453PMC13182425 | 2026-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Phase 3 Trial of Brepocitinib in Dermatomyositis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41910335无 PMCID | 2026-May-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42127390无 PMCID | 2026-May-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42127391无 PMCID | 2026-May-14 | 0.85 | The study is a Phase III randomized trial of a drug intervention in humans with original results, but it investigates IgA nephropathy (a kidney disease), not a human malignant neoplasm. Additionally, the primary endpoint is a change in proteinuria (protein-to-creatinine ratio), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. | 无 KM 图 |
| Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial.BMJ疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig 1:图注未提示 KM 曲线;Fig 2:森林图/亚组分析图。 | PMID 42128454PMC13170071 | 2026-May-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41670573无 PMCID | 2026-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41984450PMC13084553 | 2026-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.J Natl Compr Canc NetwPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42119607无 PMCID | 2026-May-12 | 0.95 | This is an original Phase III randomized trial in human oncology patients with a drug intervention, but its primary efficacy endpoint is a pain score (NRS), not a time-to-event outcome like OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios for such endpoints. | 无 KM 图 |
| Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.J Clin Oncol | PMID 41894648PMC13166072 | 2026-May-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42102826无 PMCID | 2026-May-09 | 0.90 | The study is a randomized, population-based, Phase III trial in colorectal cancer prevention, but the intervention is colonoscopy screening (non-drug). The primary endpoints are cancer incidence and mortality as risk ratios, not time-to-event outcomes like OS, PFS, DFS, etc., or Kaplan-Meier/HR results. Therefore, it does not meet the required criteria for a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41910380无 PMCID | 2026-May-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42090792无 PMCID | 2026-May-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42090793无 PMCID | 2026-May-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.Rheumatology (Oxford)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。 | PMID 41838419PMC13198880 | 2026-May-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线;Fig. 4:图注未提示 KM 曲线。 | PMID 42082491PMC13342565 | 2026-May-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41855781无 PMCID | 2026-May-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |